NovaBay Pharmaceuticals Inc. [AMEX: NBY] traded at a low on 06/11/20, posting a -6.15 loss after which it closed the day’ session at $0.86. The results of the trading session contributed to over 3817783 shares changing hands. Over the past one week, the price volatility of NovaBay Pharmaceuticals Inc. stands at 10.58% while the volatility over the past one month is 6.60%.
The market cap for NBY stock reached $24.11 million, with 27.98 million shares outstanding and 16.98 million shares in the current float. Compared to the average trading volume of 4.73M shares, NBY reached a trading volume of 3817783 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about NovaBay Pharmaceuticals Inc. [NBY]?
Ladenburg Thalmann have made an estimate for NovaBay Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on September 18, 2019. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on July 06, 2018, representing the official price target for NovaBay Pharmaceuticals Inc. stock. Previously, the target price had yet another drop from $10 to $8, while Laidlaw kept a Buy rating on NBY stock.
The Average True Range (ATR) for NovaBay Pharmaceuticals Inc. is set at 0.08, with the Price to Sales ratio for NBY stock in the period of the last 12 months amounting to 3.44.
How has NBY stock performed recently?
NovaBay Pharmaceuticals Inc. [NBY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.20. With this latest performance, NBY shares dropped by -13.62% in over the last four-week period, additionally plugging by 49.86% over the last 6 months – not to mention a drop of -59.87% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for NBY stock in for the last two-week period is set at 49.31, with the RSI for the last a single of trading hit 45.30, and the three-weeks RSI is set at 49.08 for NovaBay Pharmaceuticals Inc. [NBY]. The present Moving Average for the last 50 days of trading for this stock 0.8942, while it was recorded at 0.8801 for the last single week of trading, and 0.6707 for the last 200 days.
NovaBay Pharmaceuticals Inc. [NBY]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and NovaBay Pharmaceuticals Inc. [NBY] shares currently have an operating margin of -140.02 and a Gross Margin at +73.66. NovaBay Pharmaceuticals Inc.’s Net Margin is presently recorded at -146.79.
Return on Total Capital for NBY is now -185.30, given the latest momentum, and Return on Invested Capital for the company is -301.21. Return on Equity for this stock declined to -326.88, with Return on Assets sitting at -94.14. When it comes to the capital structure of this company, NovaBay Pharmaceuticals Inc. [NBY] has a Total Debt to Total Equity ratio set at 415.83. Additionally, NBY Total Debt to Total Capital is recorded at 80.61, with Total Debt to Total Assets ending up at 36.06. Long-Term Debt to Equity for the company is recorded at 51.90, with the Long-Term Debt to Total Capital now at 10.06.
Reflecting on the efficiency of the workforce at the company, NovaBay Pharmaceuticals Inc. [NBY] managed to generate an average of -$345,964 per employee. Receivables Turnover for the company is 2.89 with a Total Asset Turnover recorded at a value of 0.64.NovaBay Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.30 and a Current Ratio set at 1.40.
Earnings analysis for NovaBay Pharmaceuticals Inc. [NBY]
With the latest financial reports released by the company, NovaBay Pharmaceuticals Inc. posted -0.14/share EPS, while the average EPS was predicted by analysts to be reported at -0.07/share.When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -100.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NBY.
Insider trade positions for NovaBay Pharmaceuticals Inc. [NBY]
There are presently around $0 million, or 6.30% of NBY stock, in the hands of institutional investors. The top three institutional holders of NBY stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 75,327, which is approximately -64.562% of the company’s market cap and around 0.60% of the total institutional ownership; VIRTU FINANCIAL LLC, holding 71,169 shares of the stock with an approximate value of $65000.0 in NBY stocks shares; and VANGUARD GROUP INC, currently with $64000.0 in NBY stock with ownership of nearly 121.03% of the company’s market capitalization.
Positions in NovaBay Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 7 institutional holders increased their position in NovaBay Pharmaceuticals Inc. [AMEX:NBY] by around 148,695 shares. Additionally, 5 investors decreased positions by around 151,984 shares, while 6 investors held positions by with 39,748 shares. The mentioned changes placed institutional holdings at 340,427 shares, according to the latest SEC report filing. NBY stock had 4 new institutional investments in for a total of 70,344 shares, while 1 institutional investors sold positions of 8 shares during the same period.